ID: ALA4793115

Max Phase: Preclinical

Molecular Formula: C17H22N2O6

Molecular Weight: 350.37

Molecule Type: Unknown

Representations

Canonical SMILES:  Cc1[nH]nc(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c1Cc1ccccc1

Standard InChI:  InChI=1S/C17H22N2O6/c1-9-11(7-10-5-3-2-4-6-10)16(19-18-9)25-17-15(23)14(22)13(21)12(8-20)24-17/h2-6,12-15,17,20-23H,7-8H2,1H3,(H,18,19)/t12-,13-,14+,15-,17+/m1/s1

Standard InChI Key:  OFVXIEBOPMVNOI-GAGVYUBLSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 350.37

Molecular Weight (Monoisotopic): 350.1478

AlogP: -0.51

#Rotatable Bonds: 5

Polar Surface Area: 128.06

Molecular Species: NEUTRAL

HBA: 7

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.20

CX Basic pKa: 1.69

CX LogP: 0.59

CX LogD: 0.59

Aromatic Rings: 2

Heavy Atoms: 25

QED Weighted: 0.49

Np Likeness Score: 0.82

References

1. Shimizu K,Fujikura H,Fushimi N,Nishimura T,Tatani K,Katsuno K,Fujimori Y,Watanabe S,Hiratochi M,Nakabayashi T,Kamada N,Arakawa K,Hikawa H,Azumaya I,Isaji M.  (2021)  Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.,  34  [PMID:33581390] [10.1016/j.bmc.2021.116033]

Source

Source(1):

• Scientific Literature